Rhizome AI Gives Pharma Companies the FDA Answers They Used to Pay Consultants $500 an Hour For

The Macro: $8 Trillion in Market Cap Needs to Know What the FDA Thinks

Pharmaceutical companies, biotech startups, medical device makers, and regulatory consultants all share one obsession: understanding what the FDA will and will not approve. Every drug submission, every device clearance, every clinical trial design depends on interpreting thousands of guidance documents, advisory committee transcripts, approval letters, and enforcement actions.

The traditional way to answer a regulatory question is to hire a consultant at $300 to $500 an hour, or have an internal regulatory affairs team spend days searching through FDA databases, reading documents, and synthesizing an answer. The FDA publishes an enormous amount of information, but it is scattered across dozens of databases with different formats, search interfaces, and access methods.

Generic AI tools like ChatGPT are dangerous here because they hallucinate. In regulatory work, a hallucinated citation or an incorrect interpretation of FDA guidance can derail a submission, trigger a warning letter, or waste months of development time. You need answers that are grounded in actual documents with verifiable citations.

Rhizome AI, backed by Y Combinator, is built specifically for this problem. They have indexed 2.5 terabytes of authoritative regulatory and clinical data across 30 datasets and 6 markets, and their system returns answers backed by up to 1,000 source documents with page-level citations.

The Micro: Zero Hallucinations Reported

Chetan Mishra founded Rhizome as a solo technical founder. He started as a research engineer, worked as founding product engineer at EvolutionaryScale, and was employee number 16 at Instabase where he closed $7M as technical lead. The regulatory domain expertise came from working with pharma customers and recognizing the information retrieval problem was both massive and poorly served.

The product covers FDA premarket and postmarket databases, EMA datasets, guidance documents, clinical trials, and regional regulatory data. Enterprise customers get access to Asian markets including Korea, China, and Japan. The pricing ranges from $400 per month for individual projects up to $20,000 per year for business teams, with custom enterprise pricing for large organizations.

The standout claim is “no hallucinations reported in 2025.” In a domain where accuracy is non-negotiable, this is the metric that matters. Every statement in a Rhizome response includes a citation to a specific document and page, so users can verify claims directly.

Competitors include Veeva Vault (which handles regulatory document management but not AI-powered Q&A), IQVIA’s regulatory solutions, and generic research tools. None of them combine the depth of indexed regulatory data with a natural language interface and citation-level grounding.

The company already has 20+ customers including pharma companies, biotech startups, and regulatory consultants. At a team size of one with real revenue and real customers, Rhizome demonstrates the leverage that a focused AI product can create.

The Verdict

Rhizome AI is targeting one of the highest-value information retrieval problems in existence. The pharma and biotech industry spends billions on regulatory strategy, and much of that spend goes to answering questions that a well-indexed AI could handle faster and more comprehensively.

At 30 days: is customer retention strong after the first month? Regulatory teams that get accurate, cited answers quickly tend to become dependent on the tool.

At 60 days: how is the expansion into EMA and Asian regulatory markets going? Each new jurisdiction requires indexing a different set of databases and understanding different regulatory frameworks.

At 90 days: are any large pharma companies using Rhizome as a standard tool across their regulatory affairs teams? Enterprise adoption is where this business scales.

I think Rhizome AI has found an incredibly high-value niche. Regulatory intelligence is one of those markets where accuracy is worth a premium and the switching cost is low because the alternative is manual research. If the no-hallucination track record holds, this becomes indispensable.